Top Articles

For August 2020, we have selected Turner R.S. et al. “Nilotinib Effects on Safety, Tolerability,and Biomarkers in Alzheimer’s Disease” Annals of Neurology 2020;88:183–194. doi: 10.1002/ana.25775. Epub 2020 May 28.

Executive Page: Thomas Berger, Chair of the Scientific Committee

For August 2020, we have selected Rogers J.P. et al. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic” Lancet Psychiatry 2020; 7:611-627.

The COVID-19 Pandemic and Neurology Published by the Turkish Neurological Society COVID-19 COMMITTEE

Acute symptomatic seizures and SARS-CoV-2 encephalitis in COVID-19

COVID Breaking news: CNS injury biomarkers elevated in COVID patients

Estonia is a small country in Northeastern Europe, the northernmost of the three Baltic states.

For July 2020, we have selected: Yang P. et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke

A letter from Elena Moro as new Secretary General

Members of the EAN Scientific Panel on Infectious Diseases have recently published a systematic review of neurological manifestations of SARS‐CoV‐2 infection in the European Journal of Neurology.

EAN Scientific Panel Neuro-oncology invites you to take part in their survey:

The first case of COVID-19 infection was recorded in Brazil on Feb 25, 2020. On June 20th, official statistics reported 1 million confirmed cases, and more than 50,000 deaths. Brazil has the second highest number of cases of COVID-19 in the world, facing more than 1,000 deaths per day. However, due to underreporting among many regions in the country, the actual numbers are unknown. Besides the underestimation of the real deaths and cases, the Government recently changed the way in which the cases were reported: only new cases were reported, and not the total number of infected people or deaths. This has produced great criticism from the scientific community and the media, increasing the levels of tension under which the country has been living.

In this paper, just published in Lancet, the authors performed a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine in Wuhan, China.

From the Spanish Society of Neurology, it is our pleasure to share with our European colleagues the Handbook on COVID-19 management for Neurologists.

On June 3, we published in the Breaking News section of this site the article entitled “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” previously published in Lancet. On June 13, the article was retracted by three of the four authors.